MTOR and laminopathy: Several preclinical therapeutic strategies have shown promise in laminopathies, including p38α mitogen-activated protein kinase (MAPK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors and nicotinamide riboside, a precursor to nicotinamide adenine dinucleotide (NAD+) (Heller et al., 2020).